Crowdstrike Holdings Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Crowdstrike Holdings Inc trades at $206.77 (market cap $214.58B), while State Street SPDR S&P Biotech ETF trades at $156.04. Which is the better fit depends on your goals.
| CRWD | XBI | |
|---|---|---|
Market Cap | $214.58B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $210.73 | $164.28 |
52-Week Low | $87.56 | $85.16 |
Enterprise Value | $210.85B | — |
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $187.91, up 0.39% on the day, with a bullish technical signal and strong support near $185. The stock has delivered three consecutive quarterly EPS beats, with Q2 2026 expected at $0.29. Revenue growth remains robust, rising from $1.5B in 2022 to $4.0B in 2025, though net margins are slightly negative. A recent 4-for-1 stock split on July 2, 2026, has increased accessibility amid heightened investor interest in AI-driven cybersecurity.
Outlook is supported by solid cash flow growth and dominant market positioning, but premium valuations (P/E 765, P/S 37) pose risks if growth decelerates. Analyst consensus is strongly bullish with a $184.39 price target, though competitive pressures and execution challenges remain key watchpoints for sustained upside.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Trailing returns across standard periods
Latest headlines on both assets
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →